Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

lead investigational drug which is in late phase 3 studies for the treatment of the signs and symptoms of osteoarthritis.

For the nine months ended September 30, 2008, the net loss amounted to EUR49.7 million compared to EUR13.7 million for the first nine months of 2007. On September 30, 2008, the Company's current and non-current financial instruments and cash and cash equivalents were EUR124.8 million, compared to EUR172.8 million on December 31, 2007.

Review of the consolidated financial results for the nine months ended September 30, 2008 and 2007:

Revenues

NicOx' revenues totaled EUR2.9 million for the nine months ended September 30, 2008, compared to EUR18.4 million for the nine months ended September 30, 2007. This significant decrease is explained by the fact that the Company received EUR10.0 million from Merck and EUR1.0 million from Pfizer in 2007, which was entirely recognized as revenues in the first nine months of 2007.

For the first nine months of 2008, NicOx recognized the following amounts in revenues:

- EUR0.25 million corresponding to the initial payment of

EUR5.0 million from Pfizer, as a technology exclusivity fee, following

the March 2006 agreement that granted Pfizer rights to apply NicOx'

proprietary technology in a drug discovery research program covering

the field of ophthalmology

- EUR2.1 million corresponding to the funding of the research

collaboration, pursuant to the above referenced agreement signed with

Pfizer in March 2006

- EUR0.56 million corresponding to the balance of the spreading of the

initial payment of EUR9.2 million received from Merck following the

signature of a collaboration agreement for new antihypertensive drug

candidates in March 2006

These amounts initially recorded as prepaid income were deferred over the estimated duration of NicOx' involvement in the research and developmen
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... , April 27, 2015  For about a ... is their ability to utilize and catabolize glucose ... cancer cells is called the ,Warburg phenomenon", that ... of high oxygen presence, leading to enhanced lactate ... cells still choose glucose fermentation. A variety of ...
(Date:4/27/2015)... Diego, Calif. (PRWEB) April 27, 2015 ... of drug and chemical toxicity carries implications for advancing ... speaker April 28 at National University , the ... and presentation by Dr. Hanzlik, a professor at the ... drug metabolism and drug design, starts at 5 p.m. ...
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... for Progress MADISON, Wis. Members of the ... story of an emerging trend in the corporate world ... , ,Lori Silverman, owner of the consulting firm Partners ... Critical Shift, explained how simply following a story arc ...
... MADISON, Wis. A nurse keys a 10-milliliter-per-hour dose ... makes a simple mistake, accidentally keying in an overdose ... to receive 25 ml of a different drug, but ... like these occur every day in hospitals across the ...
... Sonic Foundry, a provider of rich-media systems and software, ... the company has announced. , ,Sonic Foundry and media ... power Courtroom Connect's new Virtual Law Viewer ... ten Sonic Foundry MediaSite presentation recorders with the BxVideo ...
Cached Biology Technology:Storytelling makes a comeback in an unlikely place 2Storytelling makes a comeback in an unlikely place 3UW Hospital and Clinics install smart intravenous pumps 2UW Hospital and Clinics install smart intravenous pumps 3Streaming video could make courtrooms into Internet conference calls 2
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... promising new class of drug designed to target the ... system, some of the HCV strains being treated exhibited ... team of Florida State University biologists, chemists and biomedical ... identify the drug-resistant HCV strains and the molecular-level mechanisms ...
... powerful new ability to engineer the flavor and aroma of ... publishing the most comprehensive deciphering of the beer,s "proteome" ever ... that make beer "beer") appears in ACS, monthly Journal ... say they were inspired to do the research by a ...
... has "significant" potential for preventing cardiomyopathy, a form of heart ... with diabetes, scientists have concluded in a new study. Their ... high risk for diabetic cardiomyopathy, appears in ACS, bi-weekly ... and colleagues note that people with diabetes have at least ...
Cached Biology News:Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
...
... Immunogen: Partially purified chicken ... detects vitamin D receptor (VDR) from ... and fish tissues. This antibody ... glucocorticoid receptors. MA1-710 detects both ...
... AccuPrime™ Pfx DNA Polymerase is ideal ... for downstream applications such as cloning ... provided by a proprietary enzyme preparation ... sp. with proofreading (3'Cut Site5' exonuclease) ...
... The BV-10 offers precision beveling ... and 50m. The unique abrasive ... free for greater control of ... be accomplished very rapidly and ...
Biology Products: